QIAGEN to Launch Automated TB Testing Workflow and AI Risk Tool by Late 2027
Event summary
- QIAGEN plans to launch a fully automated Sample to Insight workflow for QuantiFERON latent TB testing by late 2027.
- The company is also developing an AI-enabled risk stratification tool for TB progression, targeting late 2027 release.
- The new workflow integrates Inpeco’s laboratory automation and Diasorin’s LIAISON detection systems.
- QIAGEN estimates the global latent TB testing market at 75 million tests annually, growing 4-5% per year.
The big picture
QIAGEN’s move toward full automation and AI-driven insights in latent TB testing reflects broader industry trends toward higher-throughput, data-driven diagnostics. The partnership with Inpeco and Diasorin positions QIAGEN to capture a growing share of the 75 million annual latent TB tests, particularly as demand for automated solutions increases. The integration of AI into risk stratification could further solidify QIAGEN’s leadership in TB diagnostics.
What we're watching
- Market Adoption
- Whether the automated workflow can accelerate conversion from traditional skin tests to IGRA testing, currently at 40% market penetration.
- Execution Risk
- The pace at which QIAGEN can integrate Inpeco’s automation and Diasorin’s detection systems into a seamless workflow by late 2027.
- Competitive Positioning
- How the AI-enabled risk stratification tool will differentiate QuantiFERON in the latent TB testing market.
Related topics